Why Servier’s FIREFLY-2 enrollment milestone could reshape pediatric glioma treatment
OJEMDA is already approved after relapse. FIREFLY-2 asks whether Servier can move targeted pLGG therapy earlier.
Ipsen moves closer to EU approval for Ojemda in BRAF-driven childhood brain tumors
Ipsen nears EU approval for Ojemda in BRAF-driven pediatric glioma. Explore regulatory impact, clinical implications, and long-term risks.